|
|
| |
|
|
|
|
|
|
11244 |
ºÎ»ê |
2021³âµµ Á¦17Â÷ ºÎ»ê¿ï»ê°æ³² ³úÁ¹ÁßÇÐȸ Ãß°è½ÉÆ÷Áö¿ò : 2021-12-04 |
0 |
228 |
2021-11-11 |
|
|
|
11243 |
¼¿ï |
´ëÇÑõ½Ä¾Ë·¹¸£±âÇÐȸ (¿Â¶óÀÎ) ¸¸¼º±âħ ½ÉÆ÷Áö¾ö : 2021-12-04 |
0 |
292 |
2021-11-11 |
|
|
|
11242 |
¼¿ï |
¼¼ºê¶õ½ºº´¿ø ÀçÈ°ÀÇÇаú Á¦5ȸ ¿¬¼¼ÀçÈ°ÀÇÇÐÆ÷·³ : 2021-12-04 |
0 |
392 |
2021-11-11 |
|
|
|
11241 |
Á¦ÁÖ |
´ëÇѽÉÀåÇÐȸ Á¦ÁÖÁöȸ 2021³â ¿¬¼ö°Á : 2021-12-04 |
0 |
425 |
2021-11-11 |
|
|
|
11240 |
¼¿ï |
2021³â ´ëÇѳëÀνŰæÀÇÇÐȸ Ãß°èÇмú´ëȸ : 2021-12-04 |
0 |
270 |
2021-11-11 |
|
|
|
11239 |
ÀÎõ |
Èñ±ÍÁúȯ °æ±â¼ºÏºÎ±Ç °ÅÁ¡¼¾ÅÍ ½ÉÆ÷Áö¾ö : Èñ±ÍÀ¯ÀüÁúȯ Áø´Ü ¹× À¯Àü»ó´ãÀÇ ½ÇÁ¦ : 2021-12-03 |
0 |
194 |
2021-11-11 |
|
|
|
11238 |
°æ±â |
(¿Â¶óÀÎ) ±¹¸³¾Ï¼¾ÅÍ ¾Ï°úÇÐÆ÷·³, Ç׾Ͻžళ¹ß A-Z Part 2. Ç×ü ¹× Ä¡·á¿ë ¾Ï¹é½Å °³¹ß : 2021-12-03 |
0 |
364 |
2021-11-11 |
|
|
|
11237 |
°æ±â |
(¿Â¶óÀÎ) ´ëÇѼÒȱ⳻½Ã°æÇÐȸ °æ±âÀÎõÁöȸ Á¦9Â÷ ÇмúÁý´ãȸ : 2021-12-03 |
0 |
267 |
2021-11-11 |
|
|
|
11236 |
¼¿ï |
2021³â Áß¾ÓÀÇ´ë ºñ´¢À¶ÇÕ ¹× ¿À°¡³ëÀÌµå ¼¼¹Ì³ª : 2021-12-03 |
0 |
242 |
2021-11-11 |
|
|
|
11235 |
´ë±¸ |
´ëÇѸ¶ÃëÅëÁõÀÇÇÐȸ ´ë±¸.°æºÏÁöȸ Á¦243Â÷ Áý´ãȸ : 2021-12-03 |
0 |
343 |
2021-11-11 |
|
|
|
11234 |
¼¿ï |
(¿Â¶óÀÎ) Á¦ 5ȸ ÀÇÇб³À°Æò°¡ ÄÁÆÛ·±½º : 2021-12-02 |
0 |
158 |
2021-11-11 |
|
|
|
11233 |
´ëÀü |
2021 ´ëÇÑ°¡Á¤ÀÇÇÐȸ ´ëÀüÁöȸ Ãß°èÇмú´ëȸ : 2021-12-02 |
0 |
186 |
2021-11-11 |
|
|
|
11232 |
¼¿ï |
2021 ¸¶Æ÷±¸ ÀÇ»çȸ ¿¬¼ö±³À° : 2021-12-02 |
0 |
206 |
2021-11-11 |
|
|
|
11231 |
°æ±â |
Çѱ¹¿©ÀÚÀÇ»çȸ Achieving optimal Low Density Lipoprotein-Cholesterol(LDL-C) Goal with Ezetimibe and Atorvastatin : 2021-12-02 |
0 |
227 |
2021-11-11 |
|
|
|
11230 |
¼¿ï |
Àü¹® ±âµµ°ü¸® ½Ã¹Ä·¹ÀÌ¼Ç ÈÆ·Ã : 2021-12-01 |
0 |
154 |
2021-11-11 |
|
|